목적: Chronic rhinosinusitis (CRS) is an inflammatory disease of sinonasal mucosa. Lidocaine is known to have anti-inflammatory and immunomodulatory effects. This study aimed to evaluate the anti- inflammatory effect of lidocaine-derived organic compounds in an eosinophilic CRS mouse model. 방법:A CRS mouse model was established by administrating ovalbumin and Staphylococcus aureus enterotoxin B (SEB) intranasally. Mice were treated with SEB for 16 weeks. Lidocaine and the organic compounds EI137 and EI341 (at dose of 0.5 or 5 ug/g) were administered intranasally for 8 weeks. Nasal symptoms and serum total IgE levels were assessed. Reverse-transcription polymerase chain reaction was performed to analyze IL-4, IL-10, and IFN-γ, as well as the expression of their mRNA transcription factors in the sinonasal mucosa. Histological changes were evaluated using hematoxylin and eosin and periodic acid–Schiff staining. 결과:The SEB-induced CRS mouse model showed increased Th1 and Th2 cytokine and transcription factor expression in sinonasal mucosa. EI137 significantly suppressed these cytokine and transcription factor expression. SEB-induced sinonasal mucosal inflammation and mucus- producing cells were significantly reduced by intranasal EI137 administration. However, EI341 did not exhibit anti-inflammatory effect in the CRS mouse model. EI137 and EI341 suppressed SEB-stimulated IL-4 production by splenocytes. 결론:Intranasal administration of EI137 demonstrated anti-inflammatory effects by inhibiting Th1 and Th2 cytokines and reducing sinonasal mucosal inflammation. EI137 may be a promising candidate for a topical anti-inflamma tory agent for upper airway inflammatory diseases.